Robert Huizinga Acquires 90,000 Shares of Kane Biotech Inc. (CVE:KNE) Stock

Kane Biotech Inc. (CVE:KNE) Director Robert Huizinga acquired 90,000 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were bought at an average price of C$0.13 per share, for a total transaction of C$11,250.00.

Kane Biotech Trading Up 3.8 %

Shares of KNE opened at C$0.14 on Thursday. The stock’s 50-day moving average price is C$0.14 and its 200 day moving average price is C$0.13. The company has a quick ratio of 0.39, a current ratio of 0.82 and a debt-to-equity ratio of 1,164.24. The firm has a market capitalization of C$17.89 million, a price-to-earnings ratio of -4.50 and a beta of 0.54. Kane Biotech Inc. has a 12-month low of C$0.05 and a 12-month high of C$0.17.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.